Motixafortide

Motixafortide (BKT140 4-fluorobenzoyl) is a novel CXCR4 antagonist with an IC50 vakue of ～1 nM.

Product Specifications

CAS Number

[664334-36-5]

Product Name Alternative

BKT140 (4-fluorobenzoyl) ; BL-8040; TF14016

UNSPSC

12352209

Target

CXCR

Type

Peptides

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/BKT140.html

Purity

99.76

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

O=C1[C@@]2([H])N(CCC2)C([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CSSC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](N1)CC3=CC=C(C=C3)O)=O)CCCNC(N)=N)=O)CCCNC(N)=O)=O)C(N[C@H](C(N)=O)CCCNC(N)=N)=O)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC(C4=CC=C(C=C4)F)=O)=O)=O)CC5=CC6=C(C=CC=C6)C=C5)=O)=O)CC7=CC=C(C=C7)O)=O)CCCNC(N)=O)=O)CCCCN)=O)CCCCN)=O

Molecular Formula

C97H144FN33O19S2

Molecular Weight

2159.52

References & Citations

[1]Peled A, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cellsin patients with multiple myeloma. Clin Cancer Res. 2014 Jan 15;20 (2) :469-79.|[2]Beider K, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2011 Mar;39 (3) :282-92.